Laura van’t Veer, PhD
Laura van’t Veer, PhD, Co-Founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for patients with breast cancer, was recognized at the Precision Medicine World Conference (PMWC) with its Luminary Award. This award recognizes those individuals who have made significant contributions to accelerate personalized medicine within the clinical setting.
As Professor of Laboratory Medicine and Director of Applied Genomics at the University California San Francisco Helen Diller Family Comprehensive Cancer Center, Dr. van ’t Veer is committed to translational medicine that aims to leverage the genomic makeup of patients’ tumors and improve their clinical outcomes. Dr. van ’t Veer has authored more than 280 peer-reviewed scientific articles and is a co-inventor on 6 patents.
Dr. van ’t Veer received the European Society for Medical Oncology life-time achievement award for translational research in breast cancer in 2007, the European Union Women Innovator Award in 2014, and in 2015, the European Patent Office’s European Inventor award in 2015. In 2019, she was recognized by 24/7 Wall Street as one of “32 Amazing Women Inventors.” Currently, Dr. van ’t Veer serves as the Biomarker Committee Chair for the Quantum Leap Healthcare–sponsored I-SPY 2 adaptive clinical trial. By using genomic information obtained from participating patients, this trial seeks to elucidate how different tumors will respond to novel drug regimens, thus improving patient outcomes.
